Inflammation in atherosclerosis. Nature
420, 868–874 (2002)
Klein, T. W.
The cannabinoid system and immune modulation. J. Leukoc. Biol.
74, 486–496 (2003)
Buckley, N. E.
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol.
396, 141–149 (2000)
SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther.
284, 644–650 (1998)
Libby, P., Ridker, P. M. & Maseri, A.
Inflammation and atherosclerosis. Circulation
105, 1135–1143 (2002)
Statins as immunomodulatory agents. Circulation
(suppl.), II15–II17 (2004)
Srivastava, M. D., Srivastava, B. I. & Brouhard, B.
Δ9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology
40, 179–185 (1998)
Zhu, L. X.
Δ-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol.
165, 373–380 (2000)
Δ9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol.
133, 124–131 (2002)
Lyman, W. D., Sonett, J. R., Brosnan, C. F., Elkin, R. & Bornstein, M. B.
Δ9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol.
23, 73–81 (1989)
Malfait, A. M.
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA
97, 9561–9566 (2000)
Sulcova, E., Mechoulam, R. & Fride, E.
Biphasic effects of anandamide. Pharmacol. Biochem. Behav.
59, 347–352 (1998)
Brenneisen, R., Egli, A., Elsohly, M. A., Henn, V. & Spiess, Y.
The effect of orally and rectally administered Δ9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int. J. Clin. Pharmacol. Ther.
34, 446–452 (1996)
Chesher, G. B., Bird, K. D., Jackson, D. M., Perrignon, A. & Starmer, G. A.
The effects of orally administered Δ9-tetrahydrocannabinol in man on mood and performance measures: a dose-response study. Pharmacol. Biochem. Behav.
35, 861–864 (1990)
Lichtman, A. H., Poklis, J. L., Poklis, A., Wilson, D. M. & Martin, B. R.
The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend.
63, 107–116 (2001)
Varvel, S. A., Hamm, R. J., Martin, B. R. & Lichtman, A. H.
Differential effects of Δ9-THC on spatial reference and working memory in mice. Psychopharmacology (Berl.)
157, 142–150 (2001)
Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L. & Ross, R.
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb.
14, 133–140 (1994)
Reddick, R. L., Zhang, S. H. & Maeda, N.
Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb.
14, 141–147 (1994)
Tangirala, R. K., Rubin, E. M. & Palinski, W.
Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res.
36, 2320–2328 (1995)
Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Immunol.
173, 5776–5785 (2004)
Daugherty, A. & Rateri, D. L.
T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circ. Res.
90, 1039–1040 (2002)
Moeller, F. & Nielsen, L. B.
Aortic recruitment of blood lymphocytes is most pronounced in early stages of lesion formation in apolipoprotein-E-deficient mice. Atherosclerosis
168, 49–56 (2003)
Song, L., Leung, C. & Schindler, C.
Lymphocytes are important in early atherosclerosis. J. Clin. Invest.
108, 251–259 (2001)
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc. Natl Acad. Sci. USA
100, 6658–6663 (2003)
In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation
104, 197–202 (2001)
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc. Res.
59, 755–766 (2003)
Kwak, B. R.
Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation
107, 1033–1039 (2003)
Δ9-THC, 11-OH-Δ9-THC and Δ9-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci. Int.
123, 159–164 (2001)
Hickey, M. J., Bullard, D. C., Issekutz, A. & James, W. G.
Leukocyte-endothelial cell interactions are enhanced in dermal postcapillary venules of MRL/fas(lpr) (lupus-prone) mice: roles of P- and E-selectin. J. Immunol.
168, 4728–4736 (2002)
Veillard, N. R., Steffens, S., Burger, F., Pelli, G. & Mach, F.
Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler. Thromb. Vasc. Biol.
24, 2339–2344 (2004)